Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR) will merge with OnCore Biopharma to create a global hepatitis B virus infection company dedicated to developing a curative regimen by combining multiple therapeutic approaches. The stock price surged $7.78 to $23.48.